Industry
Biotechnology
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Loading...
Open
127.34
Mkt cap
7.3B
Volume
399K
High
127.34
P/E Ratio
-15.54
52-wk high
161.00
Low
120.77
Div yield
N/A
52-wk low
90.13
Portfolio Pulse from Benzinga Newsdesk
November 29, 2023 | 9:35 am
Portfolio Pulse from Benzinga Newsdesk
November 20, 2023 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
November 15, 2023 | 1:11 pm
Portfolio Pulse from Benzinga Insights
November 09, 2023 | 2:00 pm
Portfolio Pulse from Benzinga Newsdesk
November 09, 2023 | 1:57 pm
Portfolio Pulse from Benzinga Insights
November 07, 2023 | 9:15 pm
Portfolio Pulse from saritha@benzinga.com
November 07, 2023 | 9:11 pm
Portfolio Pulse from Benzinga Insights
November 06, 2023 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2023 | 12:39 pm
Portfolio Pulse from Benzinga Newsdesk
October 26, 2023 | 12:32 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.